
-
Coherus BioSciences Inc. NasdaqGM:CHRS Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. The company was incorporated in 2010 and is based in Redwood City, California.
Location: 333 Twin Dolphin Drive, Redwood City, CA, 94065, United States | Website: https://www.coherus.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
310.1M
Cash
82.41M
Avg Qtr Burn
N/A
Short % of Float
29.89%
Insider Ownership
6.54%
Institutional Own.
54.50%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CIMERLI (CHS-201) (Lucentis biosimilar) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Approved Quarterly sales | |
UDENYCA® ONBODY Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
YUSIMRY (CHS-1420) (Humira® Biosimilar (adalimumab)) (Anti-TNF) Details Arthritis, Psoriasis, Inflammatory disease | Approved Quarterly sales | |
LOQTORZI (Toripalimab) + Chemotherapy Details Nasopharyngeal carcinoma | Approved Quarterly sales | |
UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Toripalimab (anti-PD-1 antibody)(JUPITER-06) + Chemotherapy Details Esophageal Squamous Cell Carcinoma | Phase 3 Update | |
LOQTORZI (Toripalimab) + INO 3112 Details HPV+ oropharyngeal cancer, Cancer | Phase 3 Initiation | |
Casdozokitug (casdozo) combination Details Hepatocellular carcinoma | Phase 2 Update | |
Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details Non-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s | Phase 1/2 Data readout | |
Casdozokitug (casdozo) Details Non-small cell lung carcinoma (NSCLC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1/2 Update | |
LOQTORZI (Toripalimab) + STC-15 Details Non-small cell lung cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Melanoma, Endometrial cancer | Phase 1/2 Update | |
CHS-114 (SRF114) Details Head and neck squamous cell carcinoma (HNSCC), gastric cancer | Phase 1 Data readout | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + Chemotherapy Details Cancer, Small cell lung cancer | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + anti-TIGIT Details Non-small cell lung carcinoma, Cancer | Failed Discontinued | |
CHS-131 Details Multiple sclerosis, Non-alcoholic steatohepatitis | Failed Discontinued |